Literature DB >> 25630796

Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study.

N Ortonne1,2,3, L Valeyrie-Allanore3,4, S Bastuji-Garin3,5, J Wechsler1, S de Feraudy1, T-A Duong3,4, M-H Delfau-Larue2,3,6, O Chosidow3,4, P Wolkenstein3,4, J-C Roujeau3.   

Abstract

BACKGROUND: The histopathological features of drug rash with eosinophilia and systemic symptoms (DRESS) syndrome remain poorly characterized.
OBJECTIVES: To better characterize the histopathological features of DRESS syndrome, and define the phenotype of the effector cells in the skin and compare it with maculopapular rash (MPR).
METHODS: We conducted a retrospective study on 50 skin biopsies from patients with DRESS syndrome (n = 36). Histopathological and immunophenotypical features were studied and compared with a series of MPRs (n = 20).
RESULTS: Foci of interface dermatitis, involving cutaneous adnexae, were frequently seen in cases of DRESS. Eosinophils were seen in only 20% of cases and neutrophils in 42%. Eczematous (40%), interface dermatitis (74%), acute generalized exanthematic pustulosis-like (20%) and erythema multiforme-like (24%) patterns were observed. The association of two or three of these patterns in a single biopsy was significantly more frequent in cases of DRESS than in a series of nondrug-induced dermatoses (P < 0.01), and appeared to be more marked in DRESS syndrome with severe cutaneous lesions (P = 0.01) than in less severe cases of DRESS and MPR. A higher proportion of CD8(+) and granzyme B(+) lymphocytes was observed in cases of DRESS with severe cutaneous eruptions (erythroderma and/or bullae). Atypical lymphocytes were found in 28% of biopsies, and expressed CD8 in most cases; a cutaneous T-cell clone was rarely found (6%).
CONCLUSIONS: The histopathology of DRESS syndrome highlights various associated inflammatory patterns in a single biopsy. Cutaneous effector lymphocytes comprise a high proportion of polyclonal CD8(+) granzyme B(+) T lymphocytes.
© 2015 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25630796     DOI: 10.1111/bjd.13683

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  22 in total

Review 1.  Drug reactions with eosinophilia and systemic symptoms.

Authors:  B Scrace; A Fityan; C Bigham
Journal:  BJA Educ       Date:  2020-01-08

Review 2.  Recent advances in the understanding of severe cutaneous adverse reactions.

Authors:  N R Adler; A K Aung; E N Ergen; J Trubiano; M S Y Goh; E J Phillips
Journal:  Br J Dermatol       Date:  2017-09-29       Impact factor: 9.302

3.  Drug Reaction with Eosinophilia and Systemic Symptoms and Agranulocytosis Presenting as Cervical Lymphadenopathy.

Authors:  Laura Chen; Clemente Chia; Anik Saha
Journal:  Hosp Pharm       Date:  2021-01-27

Review 4.  Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors.

Authors:  Benjamin C Park; Seungyeon Jung; Steven T Chen; Anna K Dewan; Douglas B Johnson
Journal:  Am J Clin Dermatol       Date:  2022-06-16       Impact factor: 6.233

Review 5.  Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)-Readdressing the DReSS.

Authors:  Hannah Stirton; Neil H Shear; Roni P Dodiuk-Gad
Journal:  Biomedicines       Date:  2022-04-26

Review 6.  Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity.

Authors:  Katherine C Konvinse; Elizabeth J Phillips; Katie D White; Jason A Trubiano
Journal:  Curr Opin Infect Dis       Date:  2016-12       Impact factor: 4.915

Review 7.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

Review 8.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist.

Authors:  Marwan H Adwan
Journal:  Curr Rheumatol Rep       Date:  2017-01       Impact factor: 4.686

Review 9.  Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances.

Authors:  Teresa Bellón
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.228

Review 10.  Eosinophils in skin diseases.

Authors:  Susanne Radonjic-Hoesli; Marie-Charlotte Brüggen; Laurence Feldmeyer; Hans-Uwe Simon; Dagmar Simon
Journal:  Semin Immunopathol       Date:  2021-06-07       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.